The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells

Cancer Letters

Volumn 333, Issue 1, 2013, Pages 124-132

  Xu, Fuqiang ^a,b   You, Xiaona ^a   Liu, Fabao ^a   Shen, Xiaohong ^a   Yao, Yuanqing ^b   Ye, Lihong ^a   Zhang, Xiaodong ^a  

^a NANKAI UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; Cell proliferation; E2F1; HBXIP; Skp2

Indexed keywords

HEPATITIS B VIRUS X INTERACTING PROTEIN; MESSENGER RNA; ONCOPROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS B VIRUS X INTERACTING PROTEIN GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; S PHASE KINASE ASSOCIATED PROTEIN 2 GENE; TRANSCRIPTION FACTOR E2F1 GENE; TUMOR GENE; TUMOR VOLUME; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PROMOTER REGIONS, GENETIC; S-PHASE KINASE-ASSOCIATED PROTEINS; UP-REGULATION;

EID: 84876083376     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.029     Document Type: Article

References (40)

1. Melegari M., Scaglioni P.P., Wands J.R. Cloning and characterization of a novel hepatitis B virus X binding protein that inhibits viral replication. J. Virol. 1998, 72:1737-1743.
2. Minczuk M., Mroczek S., Pawlak S.D., Stepien P.P. Human ATP-dependent RNA/DNA helicase hSuv3p interacts with the cofactor of survivin HBXIP. FEBS. J. 2005, 272:5008-5019.
3. Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., Reed J.C. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO. J. 2003, 22:2729-2740.
4. Fujii R., Zhu C., Wen Y., Marusawa H., Bailly-Maitre B., Matsuzawa S., Zhang H., Kim Y., Bennett C.F., Jiang W., Reed J.C. HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res. 2006, 66:9099-9107.
5. Liu S., Li L., Zhang Y., Zhao Y., You X., Lin Z., Zhang X., Ye L. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. J. Biol. Chem. 2012, 287:30228-30239.
6. Hu N., Zhang J., Cui W., Kong G., Zhang S., Yue L., Bai X., Zhang Z., Zhang W., Zhang X., Ye L. MiR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J. Biol. Chem. 2011, 286:13714-13722.
7. Zhang H., Kobayashi R., Galaktionov K., Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995, 82:915-925.
8. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
9. Kurland J.F., Tansey W.P. Crashing waves of destruction: the cell cycle and APC(Cdh1) regulation of SCF(Skp2). Cancer cell 2004, 5:305-306.
10. Suzuki S., Fukasawa H., Misaki T., Togawa A., Ohashi N., Kitagawa K., Kotake Y., Liu N., Niida H., Nakayama K., Nakayama K.I., Yamamoto T., Kitagawa M. The amelioration of renal damage in Skp2-deficient mice canceled by p27 Kip1 deficiency in Skp2-/-p27-/-mice. PLoS. One. 2012, 7:e36249.
11. Nelsen C.J., Hansen L.K., Rickheim D.G., Chen C., Stanley M.W., Krek W., Albrecht J.H. Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2. Oncogene 2001, 20:1825-1831.
12. Shigemasa K., Gu L., O'Brien T.J., Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin. Cancer Res. 2003, 9:1756-1763.
13. Masuda T.A., Inoue H., Sonoda H., Mine S., Yoshikawa Y., Nakayama K., Mori M. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002, 62:3819-3825.
14. Sonoda H., Inoue H., Ogawa K., Utsunomiya T., Masuda T.A., Mori M. Significance of skp2 expression in primary breast cancer. Clin. Cancer Res. 2006, 12:1215-1220.
15. Shapira M., Ben-Izhak O., Linn S., Futerman B., Minkov I., Hershko D.D. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005, 103:1336-1346.
16. Traub F., Mengel M., Luck H.J., Kreipe H.H., von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res. Treat. 2006, 99:185-191.
17. Wang Z., Gao D., Fukushima H., Inuzuka H., Liu P., Wan L., Sarkar F.H., Wei W. Skp2: a novel potential therapeutic target for prostate cancer. Biochim. Biophys. Acta. 1825, 2012:11-17.
18. Li C.F., Wang J.M., Kang H.Y., Huang C.K., Wang J.W., Fang F.M., Wang Y.H., Wu W.R., Li S.H., Yu S.C., Lee J.C., Lan J., Shiue Y.L., Wu L.C., Huang H.Y. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin. Cancer Res. 2012, 18:1598-1610.
19. Hung W.C., Tseng W.L., Shiea J., Chang H.C. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett. 2010, 288:156-161.
20. Einama T., Kagata Y., Tsuda H., Morita D., Ogata S., Ueda S., Takigawa T., Kawarabayashi N., Fukatsu K., Sugiura Y., Matsubara O., Hatsuse K. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 2006, 32:376-381.
21. Bretones G., Acosta J.C., Caraballo J.M., Ferrandiz N., Gomez-Casares M.T., Albajar M., Blanco R., Ruiz P., Hung W.C., Albero M.P., Perez-Roger I., Leon J. SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells. J. Biol. Chem. 2011, 286:9815-9825.
22. Lim M.S., Adamson A., Lin Z., Perez-Ordonez B., Jordan R.C., Tripp S., Perkins S.L., Elenitoba-Johnson K.S. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 2002, 100:2950-2956.
23. Lu M., Zhao Y., Xu F., Wang Y., Xiang J., Chen D. The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer. Med. Oncol. 2012, 29:3409-3415.
24. Liang M., Liang Y.Y., Wrighton K., Ungermannova D., Wang X.P., Brunicardi F.C., Liu X., Feng X.H., Lin X. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2. Mol. Cell Biol. 2004, 24:7524-7537.
25. Stender J.D., Frasor J., Komm B., Chang K.C., Kraus W.L., Katzenellenbogen B.S. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol. Endocrinol. 2007, 21:2112-2123.
26. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
27. Nelson J.D., Denisenko O., Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat. Protoc. 2006, 1:179-185.
28. Shan C.L., Xu F.Q., Zhang S.A., You J.C., You X.N., Qiu L.Y., Zheng J.E., Ye L.H., Zhang X.D. Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2. Cell Res. 2010, 20:563-575.
29. Zhang X., Dong N., Yin L., Cai N., Ma H., You J., Zhang H., Wang H., He R., Ye L. Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J. Med. Virol. 2005, 77:374-381.
30. Hsu J.D., Kao S.H., Ou T.T., Chen Y.J., Li Y.J., Wang C.J. Gallic acid induces G2/M phase arrest of breast cancer cell MCF-7 through stabilization of p27(Kip1) attributed to disruption of p27(Kip1)/Skp2 complex. J. Agric. Food Chem. 2011, 59:1996-2003.
31. Gao D., Inuzuka H., Tseng A., Wei W. Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1. Cell Div. 2009, 4:11.
32. Wang F.Z., Sha L., Ye L.H., Zhang X.D. Promotion of cell proliferation by HBXIP via upregulation of human telomerase reverse transcriptase in human mesenchymal stem cells. Acta. Pharmacol. Sin. 2008, 29:83-89.
33. Voduc D., Nielsen T.O., Cheang M.C., Foulkes W.D. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum. Pathol. 2008, 39:1431-1437.
34. Fujita T., Liu W., Doihara H., Date H., Wan Y. Dissection of the APCCdh1-Skp2 cascade in breast cancer. Clin. Cancer Res. 2008, 14:1966-1975.
35. Radke S., Pirkmaier A., Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene 2005, 24:3448-3458.
36. Petrocca F., Visone R., Onelli M.R., Shah M.H., Nicoloso M.S., de Martino I., Iliopoulos D., Pilozzi E., Liu C.G., Negrini M., Cavazzini L., Volinia S., Alder H., Ruco L.P., Baldassarre G., Croce C.M., Vecchione A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer cell 2008, 13:272-286.
37. Chen Y.L., Uen Y.H., Li C.F., Horng K.C., Chen L.R., Wu W.R., Tseng H.Y., Huang H.Y., Wu L.C., Shiue Y.L. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann. Surg. Oncol. 2012, 10.1245/s10434-10012-12519-10438.
38. Dai H., van't Veer L., Lamb J., He Y.D., Mao M., Fine B.M., Bernards R., van de Vijver M., Deutsch P., Sachs A., Stoughton R., Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005, 65:4059-4066.
39. Aoki I., Higuchi M., Gotoh Y. NEDDylation controls the target specificity of E2F1 and apoptosis induction. Oncogene 2012, 10.1038/onc.
40. Dar A.A., Majid S., de Semir D., Nosrati M., Bezrookove V., Kashani-Sabet M. MiRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J. Biol. Chem. 2011, 286:16606-16614.